Vaxcyte, Inc. Common Stock
PCVX
$49.56
+4.42%
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on engineering high-fidelity vaccines to protect against bacterial diseases using its proprietary XpressCF cell-free protein synthesis platform. The company is a disruptive player in the vaccine space, aiming to develop superior conjugate and protein vaccine candidates for adult and pediatric indications, including its lead pneumococcal conjugate vaccine (PCV) candidates VAX-24 and VAX-31. The current investor narrative is intensely focused on the clinical and regulatory progress of these lead candidates, as the company advances toward potential commercialization, with significant attention on upcoming data readouts, manufacturing scale-up, and its positioning against established competitors in the multi-billion-dollar pneumococcal vaccine market.…
PCVX
Vaxcyte, Inc. Common Stock
$49.56
PCVX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vaxcyte, Inc. Common Stock's 12-month outlook, with a consensus price target around $64.43 and implied upside of +30.0% versus the current price.
Average Target
$64.43
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$40 - $64
Analyst target range
Insufficient detailed analyst coverage data is available to provide a consensus price target, Buy/Hold/Sell distribution, or implied upside/downside calculation. The provided data indicates coverage from 7 analysts with revenue and EPS estimates, but specific target prices are not listed. The institutional ratings history shows a consistent bullish bias, with 10 recent actions all being 'Buy' reiterations from firms including BTIG, Guggenheim, Needham, B of A Securities, and Goldman Sachs between March 2025 and February 2026. This pattern of sustained 'Buy' ratings suggests strong institutional conviction in the company's long-term pipeline potential, despite the absence of near-term revenue or profits. The lack of a published target price range typically indicates coverage is focused on the binary outcome of clinical success, and the high short ratio of 11.84 points to significant market disagreement and elevated volatility around these catalytic events.
Bulls vs Bears: PCVX Investment Factors
The bull and bear cases for Vaxcyte are in extreme tension, with the bullish thesis resting entirely on future clinical success and the bearish case grounded in present financial reality and deteriorating price action. Currently, the bear side has stronger near-term evidence, given the stock's severe 22% one-month decline, accelerating cash burn to -$669M TTM, and high short interest of 11.84%. The single most important factor in the investment debate is the binary outcome of upcoming clinical trials for VAX-24 and VAX-31. Positive data could validate the $6.3B market cap and trigger a sharp rally, while negative or ambiguous results would likely accelerate the current downtrend, forcing the company to raise capital at deeply discounted prices.
Bullish
- Strong Institutional Conviction: All 10 recent analyst actions have been 'Buy' reiterations from major firms like Goldman Sachs and B of A Securities, indicating deep-seated belief in the pipeline's long-term potential despite the lack of revenue. This unanimous bullish sentiment from sophisticated investors provides a significant vote of confidence.
- Robust Balance Sheet with Minimal Debt: The company has a fortress-like balance sheet with a current ratio of 7.91 and a debt-to-equity ratio of only 0.085, providing ample liquidity to fund its clinical programs without the immediate threat of financial distress. This strong financial position reduces dilution risk in the near term.
- Disruptive Technology in Large Market: Vaxcyte's XpressCF platform targets the multi-billion-dollar pneumococcal vaccine market with potentially superior candidates like VAX-24 and VAX-31. The company's $6.3 billion market cap reflects significant embedded optionality for successful commercialization in this massive addressable market.
- Long-Term Price Momentum Intact: Despite a recent sharp correction, the stock is still up 39.32% over the past year, indicating the underlying long-term bullish thesis remains in place. The current price of $47.30 is well above the 52-week low of $29.08, suggesting the recent sell-off may be a correction within a larger uptrend.
Bearish
- Accelerating Cash Burn & Deep Losses: Net losses are deepening rapidly, with Q4 2025 net income at -$246.5 million, up from -$166.6 million in Q2 2025. Trailing-twelve-month free cash flow is -$669.3 million, highlighting an unsustainable burn rate that necessitates future dilutive capital raises before any revenue is generated.
- Severe Recent Technical Breakdown: The stock has plummeted 22.22% over the past month and 19.16% over three months, underperforming the SPY by -27.06% in one month, signaling a powerful reversal of momentum. Trading at 73% of its 52-week range, the breakdown below key support levels suggests a shift in market sentiment from optimism to caution.
- High Short Interest & Volatility: A short ratio of 11.84 indicates significant market skepticism and bets against the stock, which can fuel exaggerated downside moves. Combined with a beta of 1.30, this creates a highly volatile and risky trading environment, especially during clinical data readouts.
- Pre-Revenue with Binary Clinical Risk: The company has zero revenue and negative traditional valuation metrics (P/E of -8.19, P/S of 0), meaning its entire $6.3 billion valuation hinges on unproven clinical success. Any setback in its lead PCV candidates could lead to a catastrophic re-rating, as seen in the stock's historical price-to-book range of 1.44 to 5.29.
PCVX Technical Analysis
The stock is in a pronounced downtrend over the short term, having declined 22.22% over the past month and 19.16% over the past three months, which sharply contrasts with its strong 1-year performance of +39.32%. Currently trading at $47.30, the price sits at approximately 73% of its 52-week range ($29.08 to $65.00), indicating it has retreated significantly from its highs and is now in the lower-middle portion of its annual band, suggesting waning momentum and potential consolidation after a prior rally. The recent momentum is decisively negative, with the 1-month decline of -22.22% and 3-month decline of -19.16% representing a significant reversal from the longer-term uptrend, signaling a potential correction or profit-taking phase; this is further evidenced by a severe negative relative strength of -27.06% versus the SPY over the past month. Key technical support is at the 52-week low of $29.08, while immediate resistance is at the recent highs near the 52-week high of $65.00; a breakdown below the recent May low of $47.17 could accelerate selling toward deeper support levels. With a beta of 1.30, the stock is 30% more volatile than the broader market, which amplifies both upside and downside moves and necessitates careful risk management, especially during this corrective phase.
Beta
1.24
1.24x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$29-$65
Price range past year
Annual Return
+43.4%
Cumulative gain past year
| Period | PCVX Return | S&P 500 |
|---|---|---|
| 1m | -5.4% | +2.1% |
| 3m | -10.7% | +12.5% |
| 6m | +15.1% | +12.4% |
| 1y | +43.4% | +26.4% |
| ytd | +6.7% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PCVX Fundamental Analysis
Vaxcyte is a pre-revenue clinical-stage company, with quarterly revenue consistently reported as $0, as all financial resources are directed toward research and development for its vaccine pipeline. The company's net loss has been deepening, with the most recent quarterly net income at -$246.5 million for Q4 2025, compared to -$212.8 million in Q3 2025 and -$166.6 million in Q2 2025, indicating an accelerating cash burn as clinical programs advance. Gross profit is negligible at $5.0 million in the latest quarter, stemming from collaborative arrangements, but operating expenses, dominated by R&D which was $242.1 million in Q4 2025, far outpace any income, resulting in an operating loss of -$274.3 million for the quarter. The balance sheet remains robust for a biotech, with a strong current ratio of 7.91 and a very low debt-to-equity ratio of 0.085, indicating minimal leverage and a liquidity-focused capital structure. However, cash flow is deeply negative, with operating cash flow of -$224.8 million and free cash flow of -$219.3 million for Q4 2025, and trailing-twelve-month free cash flow of -$669.3 million, underscoring the company's heavy dependence on external financing to fund its substantial R&D expenditures until it achieves commercialization.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-669290000.0B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PCVX Overvalued?
As Vaxcyte has no revenue and negative net income, traditional valuation metrics like P/E and P/S are not meaningful; the trailing P/E is -8.19 and the forward P/E is -6.37, reflecting expected losses, while the P/S ratio is 0. We lead with the enterprise-value-to-sales (EV/Sales) metric conceptually, though a precise figure is unavailable, as the market is valuing the company solely on its pipeline potential rather than current financials. Peer comparison to industry averages is challenging due to the lack of standard positive multiples, but the company's $6.28 billion market cap reflects significant investor expectation for future sales from its lead vaccine candidates. Historically, the stock's own valuation multiples have fluctuated widely based on clinical milestones; for instance, its price-to-book ratio has ranged from approximately 1.44 to 5.29 over the past few years, with the current P/B of 2.34 sitting near the midpoint of this historical range, suggesting a valuation that balances recent clinical progress against the ongoing high risk of development.
PE
-8.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -34x~-6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's accelerating cash consumption. Net losses deepened from -$166.6M in Q2 2025 to -$246.5M in Q4 2025, while quarterly R&D expenses hit $242.1M. With TTM free cash flow at -$669.3M and no revenue, Vaxcyte is entirely dependent on external financing. Its strong balance sheet (current ratio 7.91, D/E 0.085) provides a runway, but the burn rate implies a high probability of a dilutive equity offering within 12-18 months if clinical timelines slip.
Market & Competitive Risks are dominated by valuation compression and clinical failure. The stock trades on pure pipeline potential, making it hypersensitive to clinical news. A beta of 1.30 means it is 30% more volatile than the market, amplifying losses during sector-wide biotech sell-offs. The high short interest of 11.84% creates a crowded trade that can exacerbate declines on negative catalysts. Furthermore, the company faces entrenched competitors like Pfizer in the pneumococcal vaccine market, requiring not just clinical success but also commercial superiority.
Worst-Case Scenario involves a clinical setback for VAX-24 or VAX-31, triggering a cascade of analyst downgrades, a loss of institutional confidence, and a forced capital raise at a distressed valuation. In this scenario, the stock could rapidly re-test its 52-week low of $29.08, representing a downside of approximately -38.5% from the current price of $47.30. Given the stock's historical volatility and the binary nature of biotech investing, a drawdown to this level is a realistic, high-conviction risk for investors who mistime their entry.